Clinical Characteristics of Patients with Sars-Cov-2 Omicron Variant and COVID-19 Vaccination with Clinical Outcome Findings in Shanghai, China: A Single Center, Retrospective, Observational Study

Speaker(s)

Yang D1, Li J2, Weng H3, Lu X2, Yang W4, Jiang Q5, Chen Z6, Fang H7, Xuan J8
1Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China, 2Shanghai Centennial Scientific Co., Ltd., shanghai, China, 3Health Economic Research Institute, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guagnzhou, China, 4Shanghai Suvalue Healthcare Scientific Co., Ltd., Shanghai, China, 5The Third Affiliated Hospital of Southern Medical University, guangzhou, China, 6Department of Clinical Research Management Office, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 7Department of Anesthesiology, Zhongshan Hospital Fudan University, shanghai, China, 8Sun Yat-Sen University, Shanghai, China

Presentation Documents

OBJECTIVES: This study aimed to determine disease severity, clinical features, clinical outcome in hospitalized patients with the Omicron variant and evaluate the effectiveness of one-dose, two-dose, and three-dose inactivated vaccines in reducing viral loads, disease course, ICU admissions and severe diseases.

METHODS: Retrospective cohort analysis was performed on 5,170 adult patients (≥18 years) identified as severe acute respiratory syndrome coronavirus 2 positive with Reverse Transcription Polymerase Chain Reaction admitted at Shanghai Medical Center for Gerontology between March 2022 and June 2022. COVID-19 vaccination effectiveness was assessed using logistic regression models evaluating the association between the risk of vaccination and clinical outcomes, adjusting for confounders.

RESULTS: Among 5,170 enrolled patients, the median age was 53 years, and 2,861 (55.3%) were male. 71.0% were mild COVID-19 cases, and cough (1,137 [22.0%]), fever (592 [11.5%]), sore throat (510 [9.9%]), and fatigue (334 [6.5%]) were the most common symptoms on the patient’s first admission. Ct values increased generally over time and 27.1% patients experienced a high viral load (Ct value< 20) during their stay. 105(2.0%) of these patients were transferred to the intensive care unit after admission. 97.1% patients were cured or showed an improvement in symptoms and 0.9% died in hospital. The median length of hospital stay was 8.7±4.5 days. In multivariate logistic analysis, booster vaccination can significantly reduce ICU admissions and decrease the severity of COVID-19 outcome when compared with less doses of vaccine (OR=0.75, 95%CI, 0.62-0.91, P≤0.005; OR=0.99, 95%CI, 0.99–1.00, p＜0.001).

CONCLUSIONS: In summary, the most of patients who contracted SARSCoV-2 omicron variant had mild clinical features and patients with vaccination took less time to lower viral loads. As the COVID-19 pandemic progressed, an older and less vaccinated population was associated with higher risk for ICU admission and severe disease.

Code

CO181

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy, Electronic Medical & Health Records

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines